Zeiner Alicia, Konrad Johannes K, Hinderer Sandra, Hoess Andreas, Heinemann Sascha, Gbureck Uwe
Department for Functional Materials in Medicine and Dentistry, University Hospital Würzburg, Pleicherwall 2, 97070, Würzburg, Germany.
Department for Orthodontics, University Hospital Würzburg, Pleicherwall 2, 97070, Würzburg, Germany.
J Orthop Surg Res. 2025 Aug 22;20(1):793. doi: 10.1186/s13018-025-06217-w.
Ready-to-use non-aqueous cement pastes consist of an organic, water-miscible liquid phase in which cement powder is dispersed. While the modification of classical aqueous powder/liquid cement pastes with antibiotics has been extensively investigated, only a few studies previously published aimed at drug modification of premixed cement pastes.
A simple method for modifying such ready-to-use pastes with the model antibiotic vancomycin is described. It was demonstrated that mixing the cement paste and vancomycin solution multiple times using an adapter between two syringes resulted in macroscopically homogeneous pastes. The antibiotic-loaded cements were thoroughly characterized with regard to their physicochemical properties and their drug release profile.
Drug modification with vancomycin had no adverse effects on cement properties in terms of mechanical performance, phase composition, porosity and pore size distribution. Drug release from ready-to-use pastes exhibited a lower initial burst release of 14.5% compared to 47.9% for aqueous powder/liquid cement pastes after 24 h. At later time points, the initial exponential release kinetics slowed down due to both a decreased concentration gradient and structural changes of the cement matrix during setting. This resulted in sustained release of the antibiotic for more than 30 days. The released vancomycin maintained high antimicrobial activity against S. aureus with inhibition zones of 5.4-6.8 mm in an agar diffusion test.
The results demonstrated that modification of ready-to-use cement pastes with vancomycin is a potential candidate for clinical application, as it preserves both the material's properties and the antibiotic's activity.
即用型非水水泥浆体由一种有机的、与水混溶的液相组成,水泥粉末分散于其中。虽然用抗生素对经典的水性粉末/液体水泥浆体进行改性已得到广泛研究,但此前仅有少数已发表的研究针对预混水泥浆体的药物改性。
描述了一种用模型抗生素万古霉素对这种即用型浆体进行改性的简单方法。结果表明,使用两个注射器之间的适配器将水泥浆体和万古霉素溶液多次混合可得到宏观均匀的浆体。对载有抗生素的水泥在其物理化学性质和药物释放曲线方面进行了全面表征。
用万古霉素进行药物改性在机械性能、相组成、孔隙率和孔径分布方面对水泥性能没有不利影响。与水性粉末/液体水泥浆体在24小时后47.9%的初始突释相比,即用型浆体的药物释放在24小时后的初始突释较低,为14.5%。在随后的时间点,由于浓度梯度降低和水泥基体在凝结过程中的结构变化,初始指数释放动力学减缓。这导致抗生素持续释放超过30天。在琼脂扩散试验中,释放的万古霉素对金黄色葡萄球菌保持高抗菌活性,抑菌圈为5.4 - 6.8毫米。
结果表明,用万古霉素对即用型水泥浆体进行改性是临床应用的一个潜在候选方法,因为它既保留了材料的性能又保留了抗生素的活性。